Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Short Gut Syndrome Clear all
Terminated Phase 4 Interventional Results available

Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)

NCT00742157
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Growth Hormone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 78 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer

NCT00002520
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Prostate Cancer, Testicular Germ Cell Tumor, Tobacco Use Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
nicotine, Usual Care
Drug · Behavioral
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
19 Years to 120 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1990
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional

Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?

NCT01891279
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
elemental formula Elecare®, partially hydrolyzed formula
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 1 Year
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)

NCT00172185
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide 0.05 mg/kg/d, teduglutide 0.10 mg/kg/d
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Not applicable Interventional

Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

NCT03451253
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Short Bowel Syndrome, Ileostomy - Stoma
Interventions
amino acid mixture beverage, glucose-based sports drink
Other
Lead sponsor
Entrinsic Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Nashua, New Hampshire • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Not applicable Interventional Results available

Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

NCT01930539
View directory record Official record
Conditions
Vitamin D Deficiency, Short Bowel Syndrome
Interventions
Ultraviolet B lamp
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Not listed Not applicable Interventional

Pectin Use in Pediatric Intestinal Rehabilitation

NCT04224168
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Green Beans, Liquid Pectin
Dietary Supplement
Lead sponsor
Le Bonheur Children's Hospital
Other
Eligibility
6 Months to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational

Pediatric Teduglutide Registry

NCT04832087
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Teduglutide
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease

NCT01297933
View directory record Official record
Conditions
Cholestasis, Short Bowel Syndrome
Interventions
Omegaven
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

MENDD Tolerance Assessment Study

NCT06185088
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Coda® Balloon Catheters, Double Balloon Endoscope (DBE)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

NCT03690206
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
glepaglutide, Placebo
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years to 90 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional

Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children

NCT01194063
View directory record Official record
Conditions
Cholestasis
Interventions
Omega-3 fish oil lipid emulsion
Drug
Lead sponsor
Kapiolani Medical Center For Women & Children
Other
Eligibility
Up to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
Withdrawn Phase 3 Interventional

A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals

NCT02242656
View directory record Official record
Conditions
Short Bowel Syndrome, Short Gut Syndrome, SBS, Short Bowel, Short Gut
Interventions
Opium Tincture USP Deodorized
Drug
Lead sponsor
Marathon Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2015 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

NCT00798967
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Terminated Phase 2 Interventional Results available

Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure

NCT04604275
View directory record Official record
Conditions
Short Gut Syndrome
Interventions
Sucrase, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 7, 2026, 3:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Adaptation in Human Short Bowel Syndrome

NCT00248573
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
2
States / cities
Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

NCT00930644
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
La Jolla, California • New York, New York • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

NCT07228403
View directory record Official record
Conditions
Short Bowel Syndrome (SBS)
Interventions
Glepaglutide 10 mg
Drug
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Rochester, Minnesota • Omaha, Nebraska • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 3:15 AM EDT
No Longer Available No phase listed Expanded access

Omegaven Expanded Access Protocol

NCT02121769
View directory record Official record
Conditions
Parenteral Nutrition Associated Liver Disease
Interventions
Omegaven
Drug
Lead sponsor
St. Luke's Health System, Boise, Idaho
Other
Eligibility
Up to 17 Years
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 7, 2026, 3:15 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease

NCT01739517
View directory record Official record
Conditions
Short Bowel Syndrome, Cholestasis
Interventions
Omegaven Therapy
Drug
Lead sponsor
Amarnath, Rathna, M.D.
Individual
Eligibility
Up to 1 Year
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2012 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 4 Interventional Results available

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

NCT04555044
View directory record Official record
Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
Clinolipid, Intralipid
Drug
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
0 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Mobile, Alabama • New Haven, Connecticut • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 7, 2026, 3:15 AM EDT
Completed Phase 2 Interventional

Diet/Growth Factor Mechanisms of Gut Adaptation

NCT00067860
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
recombinant human growth hormone, diet modification
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 7, 2026, 3:15 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.

NCT05018286
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Apraglutide
Drug
Lead sponsor
VectivBio AG
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Naples, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 7, 2026, 3:15 AM EDT